Aspen Neuroscience announced completion of dosing for the first five participants in its Phase 1/2a ASPIRO clinical trial of ANPD001, an autologous neuron replacement therapy for Parkinson’s disease. According to the company, this marks an important milestone in assessing the safety and feasibility of its personalized approach.
The company said ANPD001 is manufactured from each patient’s own induced pluripotent stem cells, differentiated into dopamine-producing neurons intended to replace those lost to Parkinson’s disease. Aspen Neuroscience claims the therapy could offer a regenerative treatment option for patients with moderate to severe disease who are not adequately managed by current therapies.
According to the company, the ASPIRO trial is designed to evaluate product safety, cell survival, and potential biological effects in two sequential cohorts. The first cohort received a lower cell dose, and the study protocol includes safety reviews before moving to the higher dose group.
Aspen Neuroscience said it will continue monitoring participants and plans to share interim clinical updates as more data become available. The company claims the trial represents the first clinical evaluation of a fully personalized autologous neuron replacement therapy in Parkinson’s disease.
